UN&UP Selected to Present at BIOTECH SHOWCASE in San Francisco during JPM Conference
UN&UP was selected to present its breakthrough TheraLode™ platform at BIOTECH SHOWCASE which is taking place from January 8-10, 2024 in San Francisco, CA during the JPM Conference.
TheraLode™ magnetically unlocks the value of thrombolytics using UN&UP’s patented platform. Our thrombolytic-conjugated magnetic nanoparticles promise to destroy clots faster using a thrombolytic dose orders of magnitude lower so that the bleeding risk of standard-of-care thrombolysis is potentially eliminated. We call our unique process Magneto-Thrombolysis™.
Biotech Showcase is a premier investor conference committed to creating a platform for private and micro-mid-cap biotechnology companies, offering them a unique opportunity to showcase their innovations and engage one-to-one with investors and biopharmaceutical executives. Each year, more than 3,000 people and 2,200 companies from around the globe attend to engage more than 900 investors.
For this opportunity, UN&UP has taken advantage of the services provided by NIH SEED, whose mission is to accelerate the conversion of scientific discoveries into healthcare solutions. SEED’s core business objectives are to identify and scale approaches that enable investigators to convert scientific discoveries into impactful healthcare solutions, coordinate early-stage product development activities across the NIH, inspire and support a diverse entrepreneurial workforce, and demonstrate NIH’s role in improving patient care and driving economic growth.
For more information, please see the following:
